Navigation Links
AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
Date:12/10/2013

he 3D and placebo arms were headache, fatigue and nausea. Discontinuations due to adverse events were reported in three (1 percent) patients receiving the 3D regimen and no patients receiving placebo. Virologic relapse or breakthrough was noted in 2 percent of patients receiving the 3D regimen plus ribavirin.Additional information about AbbVie's phase III studies can be found on www.clinicaltrials.gov.

AbbVie's HCV Development ProgramThe clinical program supporting our 3D regimen includes more than 2,300 GT1 patients in more than 25 countries around the world. The AbbVie HCV clinical development program is intended to advance scientific knowledge and clinical care by investigating an interferon-free, all-oral 3D regimen with or without ribavirin with the goal of producing high SVR rates in as many patients as possible, including those that typically do not respond well to treatment, such as previous non-responders to interferon-based therapy or patients with advanced liver fibrosis or cirrhosis. Results from the remaining four studies in AbbVie's phase III program will be available in the coming months, supporting regulatory submissions starting in the second quarter of 2014.

Overview of AbbVie's phase III clinical program is as follows:StudyPatients (N)Treatment RegimenTreatment DurationSAPPHIRE-I

GT1, treatment-naive

(631)

  • ABT-450/rb +ABT-267c
  • ABT-333
  • Ribavirin
  • 12 weeks

  • Placebo
  • 12 weeks, then active treatment for 12 weeksSAPPHIRE-II

    GT1, treatment-experienced

    (394)

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 12 weeks

  • Placebo
  • 12 weeks, then active treatment for 12 weeksPEARL-II

    GT1b, treatment-experienced

    (210 a)

  • ABT-450/r +ABT-267
  • ABT-333
  • Ribavirin
  • 12 weeks

  • ABT-450/r +ABT-267 '/>"/>

  • SOURCE AbbVie Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. AbbVie Named to S&P 500 Dividend Aristocrat Index
    2. AbbVie Issues Inaugural Full-Year Outlook for 2013
    3. AbbVie to Present at Barclays Global Health Care Conference
    4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
    5. AbbVie to Host First-Quarter Earnings Conference Call
    6. AbbVie Reports First-Quarter 2013 Financial Results
    7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
    8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
    9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
    10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
    11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2014)... 17, 2014 ... ) has announced the addition of ... American Automated External Defibrillators (AED) Market" ... http://photos.prnewswire.com/prnh/20130307/600769) ,The report North American Automated ... market of devices based upon following ...
    (Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
    (Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market leader ... LeadingAge Annual Meeting in Nashville, TN. ... the market leading solution for onsite, remote medication dispensing. ... care facilities to safely and securely dispense medication onsite, ... first dose, helps ensure that the correct medication gets ...
    Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
    ... Feb. 21, 2012 ConvaTec, a world-leading developer and ... care, today announces that Ken Berger will assume the ... the ConvaTec Board of Directors. Berger joins ... last ten years, most recently as Senior Vice President ...
    ... Feb. 21, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ... overview at the Citi Global Healthcare Conference on February 27, ... New York City.   The live and archived ... of Events" in the Idenix Investor Center at ...
    Cached Medicine Technology:ConvaTec Announces the Appointment of Ken Berger to the Position of CEO Effective March 6, 2012 2
    (Date:10/20/2014)... (PRWEB) October 20, 2014 JZ Fitness, ... nutritional coaching, corporate wellness programming, authorship, international lecturing and ... excited to announce the release of the JZ Fitness ... many years of coaching thousands of individuals on nutrition, ... app that does not require calorie counting or cumbersome ...
    (Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
    (Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
    (Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
    (Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
    Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
    ... Nearly one in three women who have breast cancer ... additional surgery after the tumor is evaluated by a pathologist. ... Cancer Center cuts that number drastically by having pathologists on-site ... immediately after they are removed. Meanwhile, the surgeon and patient ...
    ... News) -- Drug-free recovery housing and day treatment programs ... who have gone through detoxification will be able to ... abuse includes both the use of illegal drugs such ... such as OxyContin, Vicodin and Percocet. Opioid addicts ...
    ... alone, approximately 6 million people suffer from an irregular ... with age, it is predicted that 15.9,million Americans will ... of AF is stroke, but,a new device from Boston ... Atritech, now part of Boston Scientific, developed the WATCHMAN ...
    ... MONDAY, Feb. 27 (HealthDay News) -- Many people with stable ... work just as well, a new study suggests. The ... a clogged artery. As many as three-quarters of these operations ... professor of medicine at Stony Brook University Medical Center in ...
    ... A great deal has been learned in the ten years ... (WHI). Hormone therapy (HT) remains the most effective treatment available ... a growing body of evidence that formulation, route of administration, ... effects. It is essential to evaluate a personal ...
    ... the country tripled to nearly three per year between 1994 ... 15 years, according to an analysis of weather conditions and ... Georgia researchers. The scientists built a detailed database ... well as the height, weight and position for 58 football ...
    Cached Medicine News:Health News:Fewer women need repeat breast cancer surgeries with new service at University of Michigan 2Health News:Drug-Free Housing Helps Heroin, Oxycontin Addicts Recover 2Health News:Stroke-preventing technology demonstrated in JoVE 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 3Health News:The North American Menopause Society (NAMS) reassures many women 2Health News:Deaths triple among football players, morning temperatures thought to play a role 2